The role of indoleamine 2, 3 dioxygenase in regulating host immunity to leishmania infection
AbstractPathogen persistence in immune-competent hosts represents an immunological paradox. Increasing evidence suggests that some pathogens, such as, Leishmania major (L. major) have evolved strategies and mechanisms that actively suppress host adaptive immunity. If this notion is correct conventional vaccination therapies may be ineffective in enhancing host immunity, unless natural processes that suppress host immunity are also targeted therapeutically. The key problem is that the basis of pathogen persistence in immune-competent individuals is unknown, despite decades of intense research. This fact, coupled with poor health care and a dearth of effective treatments means that these diseases will remain a scourge on humans unless a better understanding of why the immune system tolerates such infections emerges from research. Indoleamine 2,3-dioxygenase (IDO) has been shown to act as a molecular switch regulating host responses, and IDO inhibitor drugs shown to possess potential in enhancing host immunity to established leishmania infections. It is hoped that this review will help stimulate and help generate critical new knowledge pertaining to the IDO mechanism and how to exploit it to suppress T cell mediated immunity, thus offer an innovative approach to studying the basis of chronic leishmania infection in mice.
CitationJ Biomed Sci. 2012 Jan 9; 19(1):5
- Leishmania major attenuates host immunity by stimulating local indoleamine 2,3-dioxygenase expression.
- Authors: Makala LH, Baban B, Lemos H, El-Awady AR, Chandler PR, Hou DY, Munn DH, Mellor AL
- Issue date: 2011 Mar 1
- Indoleamine 2,3-dioxygenase (IDO) induced by Leishmania infection of human dendritic cells.
- Authors: Donovan MJ, Tripathi V, Favila MA, Geraci NS, Lange MC, Ballhorn W, McDowell MA
- Issue date: 2012 Oct
- Lysophosphatidylcholine exacerbates Leishmania major-dendritic cell infection through interleukin-10 and a burst in arginase1 and indoleamine 2,3-dioxygenase activities.
- Authors: Tounsi N, Meghari S, Moser M, Djerdjouri B
- Issue date: 2015 Mar
- Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy.
- Authors: Johnson BA 3rd, Baban B, Mellor AL
- Issue date: 2009 Jul
- Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege.
- Authors: Huang L, Baban B, Johnson BA 3rd, Mellor AL
- Issue date: 2010 Apr